Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

5-3-2019

Thermodynamic Studies of the Binding of RPC2,
([Ru(Ph₂phen)₃]²⁺),
([Ru(Ph phen) ]² ), to Purified Tubulin and Microtubules
Savannah J. West

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
West, Savannah J., "Thermodynamic Studies of the Binding of RPC2, ([Ru(Ph₂phen)₃]²⁺), to Purified
Tubulin and Microtubules" (2019). Theses and Dissertations. 4711.
https://scholarsjunction.msstate.edu/td/4711

This Graduate Thesis - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

Template B v4.0 (beta): Created by L. Threet 2/5/19

Thermodynamic studies of the binding of RPC2, ([Ru(Ph2phen)3]2+), to purified tubulin and
microtubules

By
TITLE PAGE
Savannah J. West

A Theses
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Chemistry
in Biophysical Chemistry
in the College of Arts and Sciences
Mississippi State, Mississippi
May 2019

Copyright by
COPYRIGHT PAGE
Savannah J. West
2019

Thermodynamic studies of the binding of RPC2, ([Ru(Ph2phen)3]2+), to purified tubulin and
microtubules
By
APPROVAL PAGE
Savannah J. West
Approved:
____________________________________
Edwin A. Lewis
(Major Professor)
____________________________________
Joseph P. Emerson
(Graduate Coordinator, Committee Member)
____________________________________
Nicholas C. Fitzkee
(Committee Member)
____________________________________
Rick Travis
Dean
College of Arts & Sciences

Name: Savannah J. West
ABSTRACT
Date of Degree: May 3, 2019
Institution: Mississippi State University
Major Field: Chemistry
Major Professor: Edwin A. Lewis
Title of Study: Thermodynamic studies of the binding of RPC2, ([Ru(Ph2phen)3]2+), to purified
tubulin and microtubules
Pages in Study: 38
Candidate for Degree of Chemistry
Tubulin and elastin-like polypeptides (ELPs) both form large protein structures which
can be thermodynamically evaluated using isothermal titration calorimetry and differential
scanning calorimetry. ELPs are thermos-responsive biopolymers that undergo phase separation
and form coacervates when heated. This project assesses the liquid-liquid phase separation of an
ELP sequence derived from tropoelastin with a SynB1 cell-penetrating peptide attached to the Nterminus in conjunction with the chemotherapeutic drug doxorubicin. Microtubules (MTs) are a
dynamic cellular structure formed of tubulin α/β-heterodimers and are responsible for several
important cellular processes, making them a viable target for anti-cancer drugs. There has been
extensive research done to identify new ligands that show selective binding to microtubules.
Ruthenium (II) polypyridyl complexes (RPCs) have been found to promote the polymerization of
tubulin into microtubules. ITC has been used to determine the binding affinity of
[Ru(II)(Ph2phen)3]2+ (RPC2).
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CHAPTER I
INTRODUCTION TO TUBULIN AND ELASTIN-LIKE POLYPEPTIDES
Tubulin and elastin-like polypeptides (ELPs) form large protein structures which can be
thermodynamically evaluated using ITC and N-DSC. ELPs are thermo-responsive biopolymers
with the capability to undergo phase separation and form large coacervates when heated. Their
ability to phase separate from a solvated liquid to an insoluble coacervate is a promising drug
delivery vehicle that is currently under intense investigation. [1-3] A peptide sequence derived
from tropoelastin is used in this study and has a SynB1 cell-penetrating peptide, SynB1-CysELP1, attached to the N-terminus to improve ELP uptake through endocytosis. [4, 5]
The ELP phase separation process is concentration dependent [6] and noted by a lower
critical solution temperature (LCST), above which the ELPs are not soluble and form coacervate
droplets. The coacervate is formed from droplets when the interfacial tension is high enough. [7]
Turbidity measurements can be used to determine the LCST, but since this does not provide
quantitative information about the size of the coacervate. Dynamic light scattering is used to
measure the particle size. [5] Doxorubicin, a chemotherapeutic drug used as an antitumor agent
in solid tumors, was used to determine the impact of labeling on the liquid-liquid phase
separation. [5, 6, 8, 9] This study uses nano-differential scanning calorimetry to determine the
LCST of SynB1 ELPs. The use of SynB1-Cys-ELP1 in conjunction with doxorubicin have
shown an increase in the targeting and efficacy of systemically delivered therapeutics relative to
free therapeutics. [4]
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Tubulin is a family of proteins whose main function is to assemble into protofilament
strands, which twist and coalesce to form microtubules. Microtubules from mammalian brain
tissue are primarily composed of repeating α and β heterodimers. Microtubules have a large tubelike structure with a plus and minus end where the tubulin polymerizes and depolymerizes,
respectively. [10-14] Microtubules are a major component of the cytoskeleton. Motor proteins
such as kinesin use the directionality of microtubules to transport vesicles and organelles
throughout the cell. Microtubules are responsible for maintaining rigid cell structures and for the
formation of the mitotic spindle during cell mitosis, during which they significantly increase in
number and length to separate the duplicated chromosomes. [10, 11]
Cancerous cells replicate excessively, leading to an increase in the amount of
microtubules formed in preparation for cell separation. This makes microtubules a viable target
for anti-cancer alkylating agents. Ligands bind to microtubules and can be usually classified into
two groups: stabilizers and destabilizers. Stabilizing agents bind to microtubules and prevent
them from depolymerizing at the minus end and can engender significant structural changes to
the microtubule. Destabilizing agents bind to microtubules and cause them to depolymerize into
α/β heterodimers. These binding agents will prevent cell replication and can induce severe
distortions in the integrity of the cytoskeleton. [15] Drugs currently used in anticancer therapy
that target microtubules include paclitaxel and docetaxel, commercially sold as Taxol and
Taxotere. (Figure 1.1) Paclitaxel is a compound found in the bark of the pacific yew tree;
docetaxel is an analog of paclitaxel, produced synthetically. [16, 17] Platinum-based anticancer
therapy drugs have been in use for over 40 years and is used in approximately 40% of cancer
treatments. [18] However, repeated use of platinum-based drugs such as cisplatin has made some
forms of cancer more resistant to treatment using these ligands. Patients often cannot be given
2

higher doses of platinum-based drugs because of their severe side-effects and high toxicity. This
has led to an interest in ruthenium-based complexes, which have been shown to be less toxic.
Two ruthenium-based anticancer drugs have proceeded to Phase I clinical trials at this time:
KP1019 and NAMI-A. (Figure 1.2) [19,20] Dr. Frederick MacDonnell at the University of Texas
Arlington designed and synthesized ruthenium(II) polypyridyl complexes (RPCs) used in the
polymerization and isothermal titration calorimetry experiments. His research group injected
their synthesized RPCs into cancerous cells which were observed and lysed. It was found that out
of the RPCs used in the study, [Ru(Ph2phen)3]2+ (Figure 1.3) showed a high degree of
preferential binding to the cytoskeleton of the cells over the nucleus, cytoplasm, or membranebound organelles.

A.

B.
Figure 1.1

Microtubule stabilizing agents A. paclitaxel and B. docetaxel, which both bind to
the taxane site on microtubules.
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A.

B.

Figure 1.2

Ruthenium-based anticancer drugs A. KP1019 and B. NAMI-A.

Figure 1.3

Ruthenium-based polypyridyl complex [Ru(Ph2phen)3]2+.
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CHAPTER II
REVIEW OF TECHNIQUES AND INSTRUMENTS USED IN THIS STUDY
The two studies in this thesis use three principal techniques to determine the effect of
altering the solvent used in polymerization of tubulin, the addition of microtubule stabilizing and
destabilizing ligands to tubulin, and the addition of Doxorubicin to SynB1-Cys elastin-like
polypeptides.
UV-vis spectroscopy was used to determine the concentration of tubulin and to monitor
the polymerization of tubulin. A Thermo Scientific NanoDrop 2000c Spectrophotometer was
used for both measurements. The nanodrop spectrophotometer was used to determine protein
concentration and the polymerization assays were measured in a 1 cm pathlength cuvette.
Tubulin protein concentration was determined using an extinction coefficient of ε280 = 115,000
M-1 cm-1. [1] A typical tubulin polymerization assay was performed at a concentration of 2
mg/mL. The cuvette holder was preheated to 37°C and the cuvette and tubulin solution were kept
on ice before the assay to ensure that no polymerization occurred before the initial measurement.
Typical buffer conditions were: 80 mM PIPES, 1 mM GTP, 1 mM MgSO4, 1 mM EGTA, pH
6.9. [1, 2, 3] Absorbance was recorded at 340 nm and recorded every 30 seconds for a minimum
of one hour, or until the absorbance had stopped increasing or had reached a point where the
measurement was no longer accurate. An example of a tubulin polymerization assay performed
in this study is shown in Figure 2.1.
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Figure 2.1

Polymerization assay of 2 mg/mL tubulin purchased from Cytoskeleton, Inc.
Temperature was set at 37°C. The buffer was composed of 80 mM PIPES, 1 mM
GTP, 1 mM MgSO4, 1 mM EGTA, pH 6.9.

Isothermal titration calorimetry (ITC) was used to determine the thermodynamic binding
properties of docetaxel, colchicine, and RPC2 to tubulin and microtubules. [4, 5, 6, 7] A
schematic of an ITC is shown in Figure 2.2. [8] Constant heat is applied to the reference cell
heater before ligand binding, directing a feedback circuit and activating a heater on the sample
cell. Ligand is titrated into the sample cell and heat is either produced or absorbed. The power
needed to maintain equal temperatures between the reference and sample cell is measured. The
increase in the temperature of the sample cell upon addition of the ligand indicates an exothermic
reaction, whereas an endothermic reaction requires an increase in the power supplied to the
sample cell that is proportional to the change in temperature. A well designed ITC experiment
can be used to describe the binding constant (K) between molecules. It can be applied to
biomacromolecules like DNA and proteins and their interactions with ligands. The free energy
term (ΔG) can be calculated by ΔG = -RTln(K). The integrated heat of each injection provides a
8

ΔH for the process, where the ΔG and ΔH used together can yield ΔS information through ΔG =
-ΔH – TΔS.

Figure 2.2

Schematic of isothermal titration calorimeter. Includes example thermogram and
fitted curve of the reaction enthalpy.

Differential scanning calorimetry (DSC) was used to measure the temperature at which
SynB1-Cys elastin-like polypeptides (ELP) would phase separate into a coacervate when
Doxorubicin was added to the sequence. Figure 2.3 shows a schematic of the components of a
DSC. A DSC measures the amount of power needed to maintain a constant temperature between
a reference cell, containing the solvent and buffer, and a sample cell, containing the ELP
solution. The resulting thermogram displays a peak or valley, which indicates a change in the
9

state of the sample species. DSC provides an onset temperature, a temperature where the heat
capacity is at its maximum, and the total change in enthalpy for the process (Figure 2.4).

Figure 2.3

Schematic of a differential scanning calorimeter, including the reference cell
(containing the solvent) and the sample cell.

Figure 2.4

DSC curve of a 100 μM unlabeled ELP sample, scanned at a rate of 1 °C/min in
PBS buffer.
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CHAPTER III
PURIFICATION OF TUBULIN USING HIGH-MOLARITY BUFFERS
Purification of tubulin can be performed in less than 14 hours using high molarity buffers
to force microtubule associated proteins (MAPs) away from tubulin during polymerization and
depolymerization. The most well-known method of tubulin purification from mammalian brain
tissue is the Shelanski method. [1] This method involves the use of a phosphocellulose column
and can take more than three days to complete. These columns are not currently commercially
available. Additionally, the extended time required for running the protein solution through the
column media will reduce the amount of active protein in the final solution. Purified tubulin with
a high degree of activity can be purchased both with and without MAPs, but at a price that is not
always cost efficient when compared to purifying the tubulin using a phosphocellulose column
or high-molarity buffers. This research group used a modified purification process published by
Mirco Castoldi and Andrei V. Popov at the European Molecular Biology Laboratory in
Heidelberg, Germany, referred to as the Popov protocol. [2] This method uses a series of hot and
cold ultracentrifugations in high molarity buffers to purify and crowd out MAPs. This process
can be completed in less than 14 consecutive hours, significantly improving the activity of the
final protein solution. There are five centrifugation steps in the Popov protocol which, with the
exception of the first, are preceded by a cold or hot water bath to ensure complete polymerization
or depolymerization of the tubulin.
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The brain tissue was generously provided by Sansing Meat Processing (1815 County
Line Rd, Maben, MS). Brain tissue was collected from animals, harvested, where the tissue was
were kept refrigerated and brought to university research lab within 6 hours of death in a cold
PBS buffer (20 mM sodium phosphate, 150 mM NaCl, pH 7.2). The membrane around the
brains and the blood clots were removed. The cleaned brain tissue was weighed and
homogenized in a pre-cooled Warring blender with enough depolymerization buffer to cover the
surface of the tissue in the blender. The tissue was blended for approximately 2 minutes in 30
second intervals. The depolymerization buffer was comprised of 50 mM of MES (2-[Nmorpholino]ethane sulfonic acid) with 1 mM CaCl2 and titrated to a final pH of 6.6 with HCl.
First ultracentrifugation: The homogenized solution was spun in 70 mL tubes in a
Beckman Coulter ultracentrifuge using a pre-cooled Ti 45 rotor at 4°C at 19,300 rpm for one
hour. The supernatant was collected and volume measured. Equal volumes of high-molarity 1,4piperazinediethanesulfonic acid (PIPES) buffer and glycerol pre-heated to 37°C were added to
the solution. ATP and GTP were added to the mixture to achieve final concentrations of 1.5 mM
and 0.5 mM, respectively. The solution was incubated for an hour at 37°C with gentle stirring.
Second ultracentrifugation: The polymerized tubulin solution was spun at the 37°C at
44,000 rpm for forty minutes in a preheated Ti 45 rotor. The resulting pellet was collected and
reconstituted in depolymerization buffer. The solution was gently stirred in a 4°C cold water bath
for thirty minutes.
Third ultracentrifugation: The depolymerized tubulin solution was centrifuged at 30,000
RPM in a Ti 45 rotor at 4°C for forty minutes. The resulting supernatant from the third
centrifugation was mixed with equal volumes of the high-molarity PIPES buffer and glycerol,
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and ATP and GTP added for final concentrations of 1.5 mM and 0.5 mM once again. The
solution was incubated at 37°C for 45 minutes in a hot water bath with gentle stirring.
Fourth ultracentrifugation: After the second hot water bath the polymerized tubulin
solution was centrifuged at 44,000 rpm in a Ti 45 rotor for thirty minutes. The pellet was then
collected and reconstituted with approximately 20 mL of cold BRB80 buffer. BRB80 buffer is
comprised of 80 mM PIPES and 1 mM EGTA, titrated to pH 7.5 with sodium hydroxide. The
solution was gently mixed in a cold water bath for 15 minutes.
Fifth ultracentrifugation: The solution was centrifuged at 4°C in a pre-cooled Type 40
rotor at 39,600 rpm. The pellet was discarded and the supernatant was collected in 2 mL aliquots
and was flash-frozen with liquid N2 and stored at -80°C until further use. Samples of the tubulin
were analyzed using SDS-Gel electrophoresis and polymerization assays to assess the purity and
activity of the tubulin.
Purification of tubulin from two pig brains (approximately 120 mg) resulted more than 20
mL of purified protein solution with a concentration of approximately 0.8 g/mL. The
concentration was determined using the extinction coefficient ε280 = 115,000 M-1 cm-1. [2] SDS
Gel electrophoresis was used to determine the purity of the protein solution. The resulting gel
image in Figure 3.1 shows that the final solution of purified tubulin from two different trials of
the original Popov protocol both contained a single band of between 48 and 63 kDa. This is in
agreement with both the gel produced by Castoldi et al. using the Popov protocol and purchased
tubulin from Cytoskeleton, Inc. The “PC” lane represents the Castoldi purified tubulin which has
been purified using the unmodified Popov protocol. The purchased tubulin shows the purified
tubulin from a modified Shelanski purification. [1] All three gels with the final tubulin solution
showed that the protein did not contain any visible bands apart from the major band attributed to
14

the pure tubulin. The turbidity assay of the purified tubulin using the Popov protocol (Figure 3.2)
shows that the protein did not polymerize within twenty minutes, but instead aggregated over
three hours. Tubulin purified using a modified Shelanski method was purchased from
Cytoskeleton, Inc. to compare against tubulin purified using the Popov method. Polymerization
assays were used to compare their activity. All polymerization assays were performed using a
Thermo Scientific NanoDrop 2000c Spectrophotometer at 37°C. The optical density was
recorded at 340 nm for all assays. The assays of purchased tubulin had a short lag period and
then rapidly increasing in absorption before stabilizing at the maximum degree of polymerization
(Figure 3.3). The Popov protocol was reviewed and GDP was added to the cold water bath and
ultracentrifugation steps to better stabilize the tubulin heterodimers (SDS-PAGE shown in Figure
3.4). This improved the purification process so that the polymerization assay followed the
expected polymerization rate (Figure 3.5).
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Figure 3.1

SDS-PAGE of lab purified protein using the Popov protocol. Gel stained with
Coomassie blue. (A) Week 1 and (B) Week 2 of lab purified tubulin using the
modified Popov protocol.

Figure 3.2

Turbidity assay of tubulin purified using the Popov method. The tubulin was
selected from tubulin purified without the addition of GDP in the cold
centrifugations.
16

Figure 3.3

Turbidity assay of tubulin purchased from Cytoskeleton, Inc. and purified using
the Shelanski method. Tubulin concentration is 2 mg/mL.

Figure 3.4

SDS Gel electrophoresis of tubulin purification using GDP. (Left to right) 1.
GoldBio Bluestain protein ladder. 2. First centrifugation supernatant. 3. Second
centrifugation supernatant. 4. Second centrifugation depolymerized pellet solution.
5. Third centrifugation supernatant. 6. Fourth centrifugation supernatant. (No band
visible.) 7. Fifth centrifugation supernatant (final protein solution).
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Figure 3.5

Turbidity assay of tubulin purified using improved Popov method with GDP in the
cold water baths and centrifugation steps. The tubulin selected from tubulin
purified without the addition of GDP in the cold centrifugations. Note that the lack
of lag period can be attributed to the temperature of the tubulin being above ice
water temperature.

The Popov protocol is a viable method of tubulin purification that can be used in place of
the Shelanski method. It can produce approximately 15 mg of purified tubulin from 125 mg of
porcine brain tissue. The original method provided by Castoldi and Popov did not include the use
of guanosine 5’-diphosphate in their cold ultracentrifugation steps, though high concentrations of
ATP and GTP were listed to improve polymerization in the hot water baths. The addition of
GDP to the Popov protocol provided stabilization for depolymerized tubulin in the cold steps 1,
3, and 5 and greatly improved the activity of the tubulin. This modified protein purification
method does not require the use of a phosphocellulose column in high-pressure liquid
chromatography and produces a significant amount of tubulin in as little as 14 hours.
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CHAPTER IV
EFFECT OF BINDING AGENTS AND DMSO ON THE POLYMERIZATION OF TUBULIN
Microtubules have a characteristic dynamic instability which allows the protein structure
to readily lengthen or shorten as needed under different cellular conditions. [1, 2] To investigate
the effect different ligands had on the polymerization of tubulin, it was necessary to be able to
control tubulin polymerization.
UV-vis spectroscopy was used to turbidimetrically monitor the polymerization of tubulin
into microtubules. The absorbance was recorded at 340 nm, which is considered proportional to
the degree of polymerization. The polymerization assays were performed using a 1 cm
pathlength and 5 mm wide cuvette that was pre-cooled on ice. Tubulin purchased from
Cytoskeleton, Inc. (cat. #T240) was reconstituted in a pre-cooled polymerization buffer. The
Thermo Scientific NanoDrop 2000c Spectrophotometer was preheated to 37°C and the assay
performed with 2 mg/mL tubulin. The absorbance was recorded every thirty seconds for a
minimum of one hour or until the absorbance has approximately stopped increasing or could not
be recorded at any higher absorbance. Ligands were added to the polymerization buffer at a
nominal concentration of 10 μM before reconstitution. The extinction coefficient used for
determining the concentration of RPC2 was ε460 = 30,000 M-1 cm-1 and was provided by Dr. Fred
Macdonnell with the ligand samples. The extinction coefficient used for determining the
concentration of docetaxel and colchicine are ε274 = 1,730 M-1 cm-1 and ε350 = 16,600 M-1 cm-1,
respectively. [3, 4]
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Figure 4.1

Polymerization assays of 2 mg/mL tubulin at 37°C. All concentrations were 2
mg/mL and ligand concentrations were 10 μM.

The polymerization assays shown in Figure 4.1 display how tubulin of sufficient
concentration polymerizes through GTP hydrolysis linking α/β-monomers together in
protofilaments, which twist together in a cylindrical structure. [5] The RPC2 and docetaxel
ligands were stored in DMSO due to low solubility in aqueous solution. Therefore, the
polymerization assays containing approximately10 μM RPC2 or docetaxel contain 3% DMSO.
The addition of both RPC2 and docetaxel shortened the initial lag period expected in tubulin
polymerization assays before rapidly increasing in absorbance. The addition of docetaxel did not
significantly increase the concentration of microtubules at the final polymerization rate, but the
addition of RPC2 caused the final OD340 of the assay to almost double. The increase in light
scattering can be attributed to either an increase in the amount of microtubules that have formed
at the final polymerization rate or to the possibility that docetaxel and RPC2 alter the
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microtubule structure when initially binding to the tubulin α/β-heterodimers and increase
turbidity. In contrast, colchicine is verified to be a destabilizing agent. Polymerization does not
appear to occur at all, and instead is aggregating. The lag period is severely extended and the
absorbance does not level off, but rather continues increasing over an extended 11period of time
until the absorbance could no longer be accurately read in this instrument (Figure 4.2). Docetaxel
is a known microtubule stabilizer and colchicine a known destabilizing agent. Comparison of the
assays performed have shown that tubulin polymerized with RPC2 behaves more similarly to
tubulin bound with stabilizing agents than destabilizing agents.

Figure 4.2

Polymerization assays of 2 mg/mL tubulin with 10 μM at 37°C. Tubulin was
purchased from Cytoskeleton, Inc. and purified using the Shelanksi method.

Polymerization assays performed with the addition of DMSO and no ligand showed a
sharp increase in absorbance before leveling to the final absorbance, which could be attributed to
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the formation of a sheet of protofilaments before folding into the complete cylindrical
microtubule. [6, 7, 8] The sharp increase in absorbance of the ligand-bound polymerization
assays is shown to be attributed to the addition of DMSO, but the final absorbance was not
significantly affected by the solution containing 3% DMSO. Polymerization assays comparing
tubulin polymerized with 3% DMSO (v/v) and without (Figure 4.3). [8]

Figure 4.3

Polymerization assay of 2 mg/mL tubulin with and without 5% DMSO. The
tubulin sample was purchased from Cytoskeleton, Inc. and purified using the
Shelanksi method. [7]
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CHAPTER V
BIOPHYSICAL BINDING PROPERTIES OF [RU(PH2PHEN)3]2+ TO MICROTUBULES
The binding of ligands such as colchicine and docetaxel to microtubules has been
investigated for a few decades, but the thermodynamic properties of their binding had not been
successfully determined and compared to known microtubule-binding agents. [1] This study used
isothermal titration calorimetry to determine the enthalpy, entropy and free energy of these
ligands so that they could be compared to thermodynamic values for [Ru(Ph2phen)3]2+ binding to
tubulin. Docetaxel and colchicine both have known and distinct binding locations on
microtubules. Docetaxel is a tubulin-stabilizing agent that binds to the taxane site on the βsubunit of tubulin heterodimers and inhibits depolymerization of tubulin, inducing apoptosis. [2,
3, 4] Colchicine is a destabilizing binding agent, which binds between the α and β subunits and
causes rapid depolymerization, inducing apoptosis. [5] If these binding agents caused a
significant change in the polymerization or depolymerization rate mid-experiment, then the
results would be very difficult to interpret. This study manipulated the tubulin samples as
described below so that they were not capable of forming microtubules or could not polymerize
to a higher degree under experimental conditions. The control of the polymerization rate of
tubulin was controlled through careful temperature control.
Unpublished experiments by Dr. Frederick Macdonnell’s research group have shown that
paclitaxel (an analog of docetaxel) binds to microtubules and can alter its structure by
transmission electron microscopy (Figure 5.1). The microtubules increase in thickness and
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appear more rigid, with more easily definable borders. Transmission electron microscopy with
RPC2 bound microtubules showed microtubules that appear similar in length and thickness,.
Electron microscopy with destabilizing agents such as colchicine were not performed.

Figure 5.1

Transmission electron micrographs (provided by Dr. Frederick Macdonnell) of (A)
tubulin polymerized in the absence of any ligands, (B) tubulin polymerized with 10
µM paclitaxel, (C) tubulin polymerized with 10 µM RPC2. The samples were
stained with 1% (w/v) uranyl acetate on 300-mesh carbon-coated, formvar-treated
copper grids. The grids were studied in a Zeiss model 10CA electron microscope
and the bar scale is 100 nm.

Reverse titrations were used in all ITC experiments due to the extremely low solubility of
RPC2 in aqueous solutions. Typical ITC experiments involved fourteen 20 µL injections of
tubulin (~30 µM heterodimers, or 2 mg/mL) into a 1.45 mL cell of ligand solution. The ligand
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concentrations were determined using UV-vis spectroscopy and varied due to varying solubility
in the buffer solutions. The extinction coefficient used for determining the concentration of
RPC2 was ε460 = 30,000 M-1 cm-1 and was provided by Dr. Fred Macdonnell with the ligand
samples. The extinction coefficient used for determining the concentration of docetaxel and
colchicine are ε274 = 1,730 M-1 cm-1 and ε350 = 16,600 M-1 cm-1, respectively. [6, 7] Tubulin
concentration was kept below 3 mg/mL to ensure that minimal microtubule formation before any
polymerization assays were performed in preparation for ITC experiments. A MicroCal VP-ITC
(Malvern) instrument was used at 37°C, when using polymerized tubulin, and 4°C, when using
depolymerized tubulin. CHASM, an ITC data analysis program developed in the Lewis
Biophysics Laboratory, was used to fit the ITC titrations and to determine the thermodynamic
parameters, including the association constant (K) and changes in free energy (ΔG), enthalpy
(ΔH), and entropy (-TΔS). [8]
Figure 5.2 shows the integrated ITC data for the titration of docetaxel with
depolymerized tubulin and microtubules. The stoichiometry suggests a binding of 1:1
docetaxel:tubulin heterodimer at saturation for both experiments. [2, 3, 4] The ITC experiments
binding depolymerized tubulin to RPC2 or colchicine are not shown below. Injecting
depolymerized tubulin into RPC2 created excessive heat, consistent with an increase in the
microtubule polymerization rate, and produced a thermogram that could not be fitted due to the
large amount of noise in the raw data. ITC experiments injecting depolymerized tubulin into
colchicine produced insufficient heat to successfully determine the binding parameters. RPC2
binding to polymerized tubulin is shown below in Figure 5.3 and has a binding ratio of
approximately 1:1. Colchicine binds to polymerized tubulin heterodimers in approximately a 1:1
ratio. This is similar to what we see in the competitive experiment below in Figure 5.4 where
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colchicine is bound to microtubules that have been polymerized with RPC2 in the solution. The
enthalpy of these experiments greatly differs, suggesting a different binding mode of colchicine
with RPC2 polymerized microtubules.
Competitive ITC experiments show binding in a 1:1 ratio of RPC2 to microtubules
polymerized with docetaxel. The binding affinity of RPC2 appears lower than experiments
binding RPC2 to ligand-free microtubules. Microtubules polymerized with RPC2 and injected
into colchicine showed a higher binding affinity than when bound to ligand-free microtubules
and had a 1:1 binding ratio. The nonlinear regression fits of experiments binding docetaxel to
tubulin polymerized with RPC2 could not be produced as they did not release sufficient heat to
successfully determine the binding parameters. The best fit parameters, (K, ΔH, n), and the Gibbs
free energy (ΔG), and the change in entropy term (-TΔS) for each titration are shown below in
the table below.

Table 5.1

ITC-derived thermodynamic parameters for the binding of docetaxel, colchicine,
and RPC2 in non-competitive and competitive experiments

Complex

Ligand

Tubulin
MT
MT
MT
MT:DTX
MT:RPC2

Docetaxel
Docetaxel
RPC2
Colchicine
RPC2
Colchicine

K
(M-1)
8.1·106
5.5·106
4.9·106
5.0·106
2.0·106
7.6·106

ΔG
(kcal mol-1)
-9.4 ± 1.0
-9.2 ± 0.9
-9.1 ± 0.9
-9.1 ± 0.9
-8.6 ± 0.9
-9.4 ± 0.9
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ΔH
(kcal mol-1)
-28.7 ± 4.1
-33.4 ± 6.5
-16.7 ± 2.3
-12.8 ± 2.4
-14.6 ± 7.7
-33.9 ± 7.3

-TΔS
(kcal mol-1)
19.2
24.7
7.6
3.7
6.0
24.5

Figure 5.2

Nonlinear regression fits of the ITC integrated heat data for docetaxel binding to
depolymerized tubulin and microtubules.

Figure 5.3

Nonlinear regression fit of the ITC integrated heat data for RPC2 and colchicine
binding to microtubules.
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Figure 5.4

Nonlinear regression fits of the ITC integrated heat data for competitive
experiments.

Figure 5.5 compares the Gibbs free energy, enthalpy, and change in entropy of the
experiments. The Gibbs free energy of all of these experiments were very similar, with varying
entropy and enthalpy that increase in tandem and appear to compensate for one another. The
thermogram for depolymerized tubulin binding to RPC2 is not shown as the heat produced from
these injections produced irregular thermograms that could not be fitted. This is attributed to
RPC2 binding to trace amounts of tubulin heterodimers and causing polymerization of the
injected tubulin, even at 4°C. The ΔH of RPC2 binding to ligand-free microtubules and
docetaxel-bound microtubules is roughly equal to the difference of docetaxel binding to
microtubules and RPC2 binding to microtubules, indicating that the polymerized tubulin shows
preferential binding to RPC2 in this experiment. Experiments injecting microtubules formed with
RPC2 into docetaxel produced insufficient heat to determine the binding parameters, suggesting
that the altered structure of microtubules polymerized with RPC2 may have an alter taxane
binding site that does not support docetaxel binding (Figure 5.1 C).
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ITC experiments injecting depolymerized tubulin into colchicine showed little to no
binding and did not induce polymerization, which was expected from this microtubule
destabilizing agent. Injecting polymerized microtubules into colchicine showed binding without
extensive induced depolymerization under experiment conditions. The ΔH and –TΔS are larger
for colchicine binding with microtubules formed with RPC2 (Figure 5.5). Despite this binding,
the microtubules do not appear to undergo induced depolymerization. This indicates that
colchicine and RPC2 do not compete for binding locations on the of microtubule:RPC2 complex.
This is supported by the binding ratio for colchicine almost doubling when binding to RPC2polymerized microtubules. The difference in thickness and length may provide more space for
colchicine to bind to the tubulin.
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Figure 5.5

Thermodynamic profiles for ligand binding to polymerized and depolymerized
tubulin.
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CHAPTER VI
THERMAL STABILITY OF SYN-B1 ELASTIN-LIKE POLYPEPTIDE AND
DOXORUBICIN
The thermodynamic behavior of the elastin-like polypeptide (ELP) sequence SynB1-CysELP1, derived from tropoelastin, was investigated using differential scanning calorimetry. This
ELP consists of a 150 pentapeptide repeat of [VPG(V5G3A2)G]150 with a cysteine engineered
into the sequence for covalent drug attachment and a SynB1 cell-penetrating peptide at the Nterminus. The SynB1 cell-penetrating peptide is designed to increase ELP uptake by cells,
especially tumor cells via endocytosis. [1, 2] This ELP was investigated to determine its
effectiveness as a drug carrier for the thermal targeted delivery of doxorubicin (Dox). DSC
measurements show that the ELP undergoes a liquid-liquid phase separation beginning at the
lower critical solution temperature that can be enhanced by Dox labeling. The ELP phase
transition is monophasic and the transition of mixed unlabeled and Dox-label ELP is biphasic,
with the Dox-labeled ELP transition beginning at a lower temperature. The difference in the
change in enthalpy between unlabeled and Dox-labeled ELP is consistent with droplet formation
stabilized by favorable enthalpic interactions. [2]
Differential scanning calorimetry is used to analyze thermodynamic parameters of the
liquid-liquid phase transition without assumptions about the mechanism. [2, 3] Prepared ELP
samples were provided by Dr. John Correia’s research group at the University of Mississippi
Medical Center and were kept frozen at -20°C until thawed for use in DSC experimentation. The
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thermograms for unlabeled, 90% Dox-labeled, and 45% Dox-labeled ELP heated at a rate of
1°C/min are shown in Figure 21. All thermograms heated at this rate showed an asymmetrical
transition that has been previously observed in ELP liquid-liquid phase transitions [1] as a result
of molecular association and the ongoing phase change at higher temperatures. [1, 2, 3] This
shoulder produced by the continuing phase change was significantly reduced when unlabeled and
Dox-labeled ELP samples were heated at a rate of 0.2°C/min with negligible differences in
enthalpy (Figure 6.1).

Table 6.1
Sample

Thermodynamic parameters of obtained from unlabeled and Dox-labeled SynB1Cys-ELP samples
Concentration

Percent
Labelled

Scan Rate

Ti
TPeak 1 TPeak 2
ΔH
(°C)
(°C)
(°C) (kcal/mol)
Unlabeled
100 μM
1 °C/min
34.8
37.5
72.6 ± 2.0
Trial 1
± 0.2
± 0.2
Unlabeled
100 μM
1 °C/min
35.0
36.5
75.8 ± 2.0
Trial 2
± 0.2
± 0.2
Unlabeled
90 μM
1 °C/min
35.0
36.7
65.2 ± 2.0
Trial 3
± 0.2
± 0.2
Unlabeled
90 μM
0.2 °C/min 36.0
36.9
62.5 ± 2.0
Trial 4
± 0.2
± 0.2
DOX Labeled
100 μM
93%
1 °C/min
29.3
31.3
70.8 ± 2.0
Trial 1
± 0.2 ± 0.2
DOX Labeled
100 μM
90%
1 °C/min
29.5
31.2
63.5 ± 2.0
Trial 2
± 0.2 ± 0.2
DOX Labeled
100 μM
46.5%
1 °C/min
29.5
32.8
38.0 87.8 ± 2.0
Trial 3
± 0.2 ± 0.2 ± 0.2
DOX Labeled
100 μM
45.0%
1 °C/min
28.1
33.1
38.8 82.4 ± 2.0
Trial 4
± 0.2 ± 0.2 ± 0.2
DSC Ti, TPeak, and enthalpy values for unlabeled and Dox-labeled SynB1-Cys-ELP. Experiments
were run at either 90 or 100 μM at a rate of 1 °C/min, with the exception of Unlabeled ELP Trial
4, which was 0.2 °C/min. All ELP samples were in a phosphate-buffered saline (PBS) and were
provided by Dr. Jack Correia from the University of Mississippi Medical Center.
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Figure 6.1

DSC curve of unlabeled SynB1-ELP, 45% Dox-labeled SynB1-ELP, and 90%
Dox-labeled SynB1-ELP scanned at a rate of 1°C/min.

Figure 6.2

DSC curve of unlabeled SynB1-ELP scanned at a rate of 1°C/min and 0.2°C/min.
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The enthalpy of the transitions was determined by integrating the excess heat capacity of
the measured temperature range. The enthalpy values (Table 6.1) at 1°C/min were averaged over
two runs and were 76.0 kcal/mol for unlabeled ELP, 65.7 kcal/mol for 90% Dox-labeled ELP,
and 70.2 kcal/mol for 45% Dox-labeled ELP. Comparison of 1°C/min and 0.2°C/min scan rates
with unlabeled ELP showed a negligible difference between the resulting enthalpies. The 45%
Dox-labeled ELP was biphasic, consistent with the observations by Dreher et al. [4] The
enthalpic enhancement of the phase transition between unlabeled and 90% Dox-labeled ELP
extrapolated to 100% suggests that Dox-labeling has a -11.4 kcal/mol stabilizing effect on the
coacervate. The thermograms demonstrate a broad 5-6°C phase change above the initial Ti
region. The positive ΔH of the liquid-liquid phase transition is consistent with the burial of the
hydrophobic surface and the favorable change in enthalpy from Dox-labeling consistent with
direct Dox-ELP interactions in the coacervates. [2] These experiments show that the addition of
the Dox label significantly lowers the enthalpy of the transition and has a stabilizing effect on the
coacervate, plausibly through van der Waals interactions. [2, 5]
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